Background
Methods
Patients
Treatment
Follow up
Tissue microarray (TMA) construction
Immunohistochemical staining
Statistical analysis
Results
Patient characteristics
Clinicopathological features | Total | LR n (%) | NR n (%) | χ² | P | ||
---|---|---|---|---|---|---|---|
(n = 149) | 73 | 76 | |||||
Gender | |||||||
Male | 97 | 50(68.5%) | 50(65.8%) | 0.123 | 0.725 | ||
Female | 52 | 23(31.5%) | 26(34.2%) | ||||
Age (y) | |||||||
>50 | 134 | 64(87.7%) | 70(92.1%) | 0.809 | 0.369 | ||
≤ 50 | 15 | 9(12.3%) | 6(7.9%) | ||||
Tumor location from anal verge (cm) | |||||||
<5 cm | 42 | 17(23.3%) | 25(32.9%) | 4.78 | 0.092 | ||
5–10 cm | 96 | 53(72.6%) | 43(56.6%) | ||||
>10 cm | 11 | 3(4.1%) | 8(10.5%) | ||||
Tumor size (cm) | |||||||
<5 cm | 99 | 48(65.8%) | 51(67.1%) | 0.031 | 0.861 | ||
≥ 5 cm | 50 | 25(34.2%) | 25(32.9%) | ||||
TNM stage | |||||||
II | 51 | 13(17.8%) | 38(50.0%) | 17.14 | <0.001 | ||
III | 98 | 60(82.2%) | 38(50.0%) | ||||
T stage | |||||||
T2 | 7 | 2(2.7%) | 5(6.6%) | 1.266 | 0.595* | ||
T3 | 117 | 58(79.5%) | 59(77.6%) | ||||
T4 | 25 | 13(17.8%) | 12(15.8%) | ||||
N stage | |||||||
N0 | 36 | 13(17.8%) | 23(30.3%) | 6.223 | 0.045 | ||
N1 | 67 | 31(42.5%) | 36(47.4%) | ||||
N2 | 46 | 29(39.7%) | 17(22.3%) | ||||
Differentiation | |||||||
Well | 4 | 3(4.1%) | 1(1.3%) | 2.592 | 0.490* | ||
Moderately | 74 | 36(49.3%) | 38(50.0%) | ||||
Poorly | 66 | 33(45.2%) | 33(43.4%) | ||||
Unknown | 5 | 1(1.4%) | 4(5.3%) | ||||
Lymphatic vessel invasion | |||||||
+ | 17 | 16(21.9%) | 1(1.3%) | 15.636 | <0.001* | ||
- | 132 | 57(78.1%) | 75(98.7%) | ||||
Circumferential resection margin | |||||||
+ | 8 | 6(8.2%) | 2(2.6%) | 1.320 | 0.250* | ||
- | 141 | 67(91.8%) | 74(97.4%) | ||||
Longitudinal resection margin | |||||||
+ | 2 | 2(2.7%) | 0(0%) | 0.549 | 0.459* | ||
- | 147 | 71(97.3%) | 76(100%) |
Treatment | Total n = 149 | LR n (%) 73 | NR n (%) 76 | χ² | P | |
---|---|---|---|---|---|---|
Surgery | ||||||
Dixon | 83 | 34(46.6%) | 49(64.5%) | 5.51 | 0.064 | |
Miles | 43 | 27(37.0%) | 16(21.0%) | |||
Hartmann | 23 | 12(16.4%) | 11(14.5%) | |||
Radiochemotherapy | ||||||
neoadjuvant | 73 | 40(54.8%) | 33(43.4%) | 1.927 | 0.165 | |
adjuvant | 76 | 33(45.2%) | 43(56.6%) | |||
Chemotherapy regimens | ||||||
CAPE | 53 | 29(39.7%) | 24(31.6%) | 1.664 | 0.736* | |
CAPEOX | 30 | 15(20.5%) | 15(19.7%) | |||
mFOLFOX6 | 64 | 28(38.4%) | 36(47.4%) | |||
Tegafur | 2 | 1(1.4%) | 1(1.3%) |
PTEN and p-4E-BP1 might be associated with postoperative recurrence
LR group n (%) | NR group n (%) | χ² | P | |
---|---|---|---|---|
SIRT1 | ||||
- | 11(15.1%) | 14(18.4%) | 0.300 | 0.584 |
+ | 62(84.9%) | 62(81.6%) | ||
PTEN | ||||
- | 34(46.6%) | 21(27.6%) | 5.738 | 0.017 |
+ | 39(53.4%) | 55(72.4%) | ||
p-4E-BP1 | ||||
- | 19(26.0%) | 34(44.7%) | 5.687 | 0.017 |
+ | 54(74.0%) | 42(55.3%) | ||
pS6 | ||||
- | 11(15.1%) | 20(26.3%) | 2.859 | 0.091 |
+ | 62(84.9%) | 56(73.7%) |
Covariates | Sig | OR | 95% C.I. | ||
---|---|---|---|---|---|
Lower | Upper | ||||
TNM stage | |||||
II | 1 | ||||
III | <0.001 | 4.515 | 1.935 | 10.535 | |
Lymphatic vessel invasion | |||||
Negative | 1 | ||||
Positive | 0.006 | 24.97 | 2.557 | 243.815 | |
PTEN | |||||
+ | 1 | ||||
- | 0.001 | 5.312 | 1.968 | 14.337 | |
p-4E-BP1 | |||||
- | 1 | ||||
+ | 0.003 | 4.402 | 1.635 | 11.857 |